ArticleMicrobial cell factories2016
Development of an efficient autoinducible expression system by promoter engineering in Bacillus subtilis.
Article in Microbial cell factories, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 76 citations in OpenAlex.
- Multi-parameter optimization of recombinant protein secretion in Bacillus subtilis: a review.Microbial cell factories · 2026Review
- Bacterial Laccase: Recent Advances in Production, Engineering Strategies, and Diagnostic Applications.Biotechnology and bioengineering · 2026Review
- Development of Bacillus subtilis cell factories for nutraceuticals production.World journal of microbiology & biotechnology · 2026Review
- A multi-tetracycline responsive induction system for gene expression inApplied and environmental microbiology · 2026Article
- Enhanced L-tyrosine production in Bacillus amyloliquefaciens through alleviation of feedback Inhibition and coordinated pathway expression.Microbial cell factories · 2026Article
- A Multi-Tetracycline Responsive Induction System for Gene Expression inbioRxiv : the preprint server for biology · 2025Article
- Development and construction of a novel Bacillus subtilis autoinducible extracellular expression system based on a LuxI/R device.Microbial cell factories · 2025Article
- Important role of Bacillus subtilis as a probiotic and vaccine carrier in animal health maintenance.World journal of microbiology & biotechnology · 2024Review
- Regulatory RNAs inSynthetic and systems biotechnology · 2024Review
- Synthetic Homoserine Lactone Sensors for Gram-PositiveACS synthetic biology · 2024Article
- Toolbox of Characterized Genetic Parts forACS synthetic biology · 2024Article
- Implementation of Fluorescent-Protein-Based Quantification Analysis in L-Form Bacteria.Bioengineering (Basel, Switzerland) · 2024Article
- Efficient secretory expression of phospholipase D for the high-yield production of phosphatidylserine and phospholipid derivates from soybean lecithin.Synthetic and systems biotechnology · 2023Article
- Development of a Glycerol-Inducible Expression System for High-Yield Heterologous Protein Production in Bacillus subtilis.Microbiology spectrum · 2022Article
- Recent Advances in Nattokinase-Enriched Fermented Soybean Foods: A Review.Foods (Basel, Switzerland) · 2022Review
- Efficient D-allulose synthesis under acidic conditions by auto-inducing expression of the tandem D-allulose 3-epimerase genes in Bacillus subtilis.Microbial cell factories · 2022Article
- Cell-Free PURE System: Evolution and Achievements.Biodesign research · 2022Review
- The multifunctionality of expression systems inExperimental biology and medicine (Maywood, N.J.) · 2021Review
- Development and comparison of cell-free protein synthesis systems derived from typical bacterial chassis.Bioresources and bioprocessing · 2021Article
- Realization of Robust and Precise Regulation of Gene Expression by Multiple Sigma Recognizable Artificial Promoters.Frontiers in bioengineering and biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundBacillus subtilis, a Gram-positive organism, has been developed to be an attractive expression platform to produce both secreted and cytoplasmic proteins owing to its prominent biological characteristics. We previously developed an auto-inducible expression system containing the srfA promoter (PsrfA) which was activated by the signal molecules acting in the quorum-sensing pathway for competence. The P srfA promoter exhibited the unique property of inducer-free activity that is closely correlated with cell density.
resultsTo improve the PsrfA-mediated expression system to the high-cell-density fermentation for industrial production in the B. subtilis mutant strain that is unable to sporulate, a spore mutant strain BSG1682 was developed, and the PsrfA promoter was enhanced by promoter engineering. Using green fluorescent protein (GFP) as the reporter, higher fluorescent intensity was observed in BSG1682 with expression from either plasmid or chromosome than that of the wild type B. subtilis 168. Thereafter, the PsrfA was engineered, yielding a library of PsrfA derivatives varied in the strength of GFP expression. The P23 promoter exhibited the best performance, almost twofold stronger than that of P srfA. Two heterologous proteins, aminopeptidase (AP) and nattokinase (NK), were successfully overproduced under the control of P23 in BSG1682. Finally, the capacity of the expression system was demonstrated in batch fermentation in a 5-L fermenter.
conclusionsThe expression system demonstrates prominence in the activity of the auto-inducible promoter. Desired proteins could be highly and stably produced by integrating the corresponding genes downstream of the promoter on the plasmid or the chromosome in strain BSG1682. The expression system is conducive to the industrial production of pharmaceuticals and heterologous proteins in high-cell-density fermentation in BSG1682.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.